PatientsVille.com Logo

RHABDOMYOLYSIS and Ibuprofen

PatientsVille

RHABDOMYOLYSIS Symptoms and Causes

Your muscles help you move and help your body work. Different types of muscles have different jobs. There are many problems that can affect muscles. Muscle disorders can cause weakness, pain or even paralysis.

Causes of muscle disorders include

  • Injury or overuse, such as sprains or strains, cramps or tendinitis
  • A genetic disorder, such as muscular dystrophy
  • Some cancers
  • Inflammation, such as myositis
  • Diseases of nerves that affect muscles
  • Infections
  • Certain medicines

Sometimes the cause is not known.

Check out the latest treatments for RHABDOMYOLYSIS

RHABDOMYOLYSIS treatment research studies

Ibuprofen clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ibuprofen Side Effects

Renal Failure Acute (530)
Pain (458)
Vomiting (442)
Overdose (430)
Completed Suicide (430)
Nausea (410)
Dyspnoea (382)
Gastrointestinal Haemorrhage (345)
Intentional Overdose (312)
Haematemesis (282)
Abdominal Pain (269)
Dizziness (268)
Hypotension (266)
Pyrexia (240)
Renal Failure (230)
Malaise (219)
Anxiety (217)
Toxicity To Various Agents (217)
Diarrhoea (216)
Abdominal Pain Upper (214)
Gastric Ulcer (169)
Headache (166)
Cardiac Arrest (163)
Hypersensitivity (161)
Melaena (157)
Pulmonary Embolism (157)
Blood Creatinine Increased (155)
Dehydration (153)
Anaemia (153)
Death (152)
Fatigue (150)
Metabolic Acidosis (149)
Injury (149)
Pruritus (145)
Angioedema (144)
Coma (144)
Chest Pain (141)
Gastritis (137)
Haemoglobin Decreased (134)
Urticaria (133)
Deep Vein Thrombosis (132)
Asthenia (129)
Tachycardia (129)
Rash (128)
Cholelithiasis (128)
Loss Of Consciousness (127)
Cholecystitis Chronic (126)
Confusional State (123)
Somnolence (120)
Gastric Haemorrhage (118)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

RHABDOMYOLYSIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis
Conditions: Rhabdomyolysis;   Acute Kidney Failure
Intervention: Biological: Plasma NGAL level
Outcome Measures: Plasma NGAL level;   Delay between initiation of treatment and beginning of acute renal failure;   Delay between cause and treatment;   Need for extracorporeal blood purification;   Patient admitted to ICU?;   Length of hospitalization;   Patient deceased during hospitalization
2 Recruiting Myoglobin Removal by High Cut-off CVVHD
Conditions: Rhabdomyolysis;   Renal Failure
Interventions: Device: septeX;   Device: HF CVVH
Outcome Measures: Myoglobin plasma level;   eGFR;   Duration of hospital stay (days)and Duration of ICU stay (days);   Duration of dialysis dependence (days);   Diuresis / oliguria (<0.5 ml/kg/12h)/ anuria;   patient survival
3 Unknown  Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
Conditions: Rhabdomyolysis;   Myopathy;   Acute Renal Failure;   Neuroleptic Malignant Syndrome
Intervention:
Outcome Measure:
4 Recruiting Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
Condition: Rhabdomyolysis
Interventions: Device: CytoSorb Device;   Procedure: CVVH
Outcome Measures: Efficacy of device as measured by change in myoglobin;   Assessment of serious device or procedure-related adverse events
5 Recruiting Nutritional Prevention of Exertional Muscle Dysfunction
Conditions: Muscle Dysfunction;   Exertional Rhabdomyolysis;   Muscle Strength
Interventions: Dietary Supplement: Choline;   Dietary Supplement: Placebo
Outcome Measure: Creatine Kinase (CK) activity
6 Recruiting Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2
Conditions: Stroke;   Rhabdomyolysis;   Jaundice
Interventions: Drug: Lovastatin;   Other: Placebo
Outcome Measures: Increase in Liver Function Tests (LFTs);   Increase in Creatine Kinase (CK);   Score on NIH Stroke Scale;   Barthel Index Score;   Modified Rankin scores
7 Unknown  The Association of Genetic Polymorphisms With Statin-Induced Myopathy.
Conditions: Rhabdomyolysis;   Myopathy
Intervention: Genetic: DNA
Outcome Measures: genotype of specific genes;   single nucleotide polymorphism
8 Unknown  A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
Conditions: Hyperlipidemia;   Hypercholesterolemia
Interventions: Drug: ezetimibe;   Drug: niacin;   Drug: colestipol
Outcome Measures: To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient’s cardiovascular risks are assessed to determine i;   . Secondary measures examine the safety issues with liver function test (LFT) monitoring and Rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome.
9 Recruiting Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria
Condition: Malaria
Interventions: Drug: Paracetamol;   Drug: No Paracetamol
Outcome Measures: Effect of paracetamol concentrations;   Compare treatment arm with control arm with respect to duration of Acute Kidney Injury (AKI) and development of AKI.;   Oxidative stress assessed by measuring F2-isoprostanes (F2-IsoPs);   Assessment of Blackwater fever;   Mortality trends;   Intravascular Haemolysis;   Fever clearance time;   Parasite clearance time;   Parasite sequestration;   Assessment of Acute Kidney Injury;   Creatinine clearance;   Safety assessment
10 Recruiting Statins Evaluation in Coronary Procedures and Revascularization Trial
Condition: Acute Coronary Syndrome
Interventions: Drug: Atorvastatin;   Drug: Placebo
Outcome Measures: Major Cardiovascular Events (MACE);   Cardiovascular Mortality;   Revascularization of the Target Lesion;   Non-fatal Myocardial Infarction;   Stent Thrombosis;   Stroke;   Rhabdomyolysis;   Bleeding episode;   All-cause mortality;   Recurrent ischemia leading to urgent revascularization
11 Not yet recruiting Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging
Condition: Intracranial Arterial Stenosis
Intervention: Drug: Rosuvastatin
Outcome Measures: The change in the percentage of volume of MCA atherosclerosis plaque after 2 years treatment of Rosuvastatin 10-20mg;   The change in Percentage of plaque volume of M1segment plaque;   The change in Percentage of lumen volume;   The change in percentage of lipid rich necrotic core;   Recurrency of stroke or TIA;   The change of percentage in LDL-C from baseline;   The change in HDL-C level from baseline;   To explore the relationship between the change of plaque volumn and morphology and the change in LDL-C, HDL-C and Hs-CRP level;   safety-Rhabdomyolysis,Hepatonecrosis;   The change in percentage of thickness of fibrous cap;   The change in percentage of intraplaque hemorrhage;   The change in hsCRP level from baseline;   2.Severe bleeding incidence (GUSTO definition), including fatal bleeding and symptomatic intracranial hemorrhage;   Incidence symptomatic and asymptomatic intracranial hemorrhagic events at 3 months;   Moderate bleeding (GUSTO definition);   Intracranial hemorrhage;   Total mortality;   AEs/SAEs reported by the investigators
12 Not yet recruiting The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients
Conditions: Dyslipidemia;   Transplants
Intervention: Drug: Ezetimibe
Outcome Measures: Decrease of LDL cholesterol concentration.;   Change in oxidative markers
13 Unknown  West Indies-French Guiana Dengue Study
Conditions: Fever;   Dengue
Interventions: Other: biological sample collection;   Other: quality of life questionnaire EuroQol®
Outcome Measures: Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.;   Onset of dengue hemorrhagic fever (WHO criteria). Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
14 Unknown  Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation
Condition: Burns
Intervention:
Outcome Measure: